Endometrial Ablation Doesn't Increase Cancer Risk

Share this content:
Endometrial Ablation Doesn't Increase Cancer Risk
Endometrial Ablation Doesn't Increase Cancer Risk

MONDAY, Aug. 14, 2017 (HealthDay News) -- For women in Finland, endometrial ablation is not associated with increased risk of endometrial or breast cancer, according to a study published in the September issue of Obstetrics & Gynecology.

Tuuli Soini, M.D., from the Hyvinkää Hospital in Finland, and colleagues conducted a retrospective study involving women with endometrial ablation at ages 30 to 49 years in Finland. The authors examined cancer incidences in the endometrial ablation cohort compared with those in the background population of the same age.

During the follow-up of 39,892 women-years, the researchers identified 154 cancers (standardized incidence ratio, 0.96; 95 percent confidence interval, 0.82 to 1.13) among 5,484 women treated with endometrial ablation. For endometrial cancer and breast cancer, the standardized incidence ratios were 0.56 (95 percent confidence interval, 0.12 to 1.64) and 0.86 (95 percent confidence interval, 0.67 to 1.09), respectively. Overall, 19.8 percent of women had post-ablation hysterectomy. Compared with 26,938 women in a control group, the risk of hysterectomy was almost four-fold in the endometrial ablation cohort (adjusted hazard ratio, 3.63; 95 percent confidence interval, 3.32 to 3.96). Leiomyomas, age younger than 35 years, at least two prior cesarean deliveries, and history of sterilization were factors that predisposed patients to post-ablation hysterectomy.

"Endometrial ablation was not associated with an elevated endometrial cancer or breast cancer risk in Finland," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »